Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Translational Stroke Research
Erschienen in: Translational Stroke Research 2/2019

20.06.2018 | Review Article

Mitochondrial Dysfunction in Stroke: Implications of Stem Cell Therapy

verfasst von: Deepaneeta Sarmah, Harpreet Kaur, Jackson Saraf, Kanchan Vats, Kanta Pravalika, Madhuri Wanve, Kiran Kalia, Anupom Borah, Akhilesh Kumar, Xin Wang, Dileep R. Yavagal, Kunjan R. Dave, Pallab Bhattacharya

Erschienen in: Translational Stroke Research | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Stroke is a debilitating condition which is also the second leading cause of death and disability worldwide. Despite the benefits and promises shown by numerous neuroprotective agents in animal stroke models, their clinical translation has not been a complete success. Hence, search for treatment options have directed researchers towards utilising stem cells. Mitochondria has a major involvement in the pathophysiology of stroke and a number of other conditions. Stem cells have shown the ability to transfer mitochondria to the damaged cells and to help revive cell energetics in the recipient cell. The present review discusses how stem cells could be employed to protect neurons and mitochondria in stroke and also the various mechanisms involved in neuroprotection.
Literatur
1.
Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders—a step towards mitochondria based therapeutic strategies. Biochim Biophys Acta (BBA)-Mol Basis Dise. 2017;1863(5):1066–77.CrossRef
2.
J-A K, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102(4):401–14.CrossRef
3.
Oyewole AO, Birch-Machin MA. Mitochondria-targeted antioxidants. FASEB J. 2015;29(12):4766–71.CrossRefPubMed
4.
Sherratt H. Mitochondria: structure and function. Rev Neurol. 1991;147(6–7):417–30.PubMed
5.
Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem. 2002;80(5):780–7.CrossRefPubMed
6.
7.
Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210–5.CrossRefPubMed
8.
Neri M, Fineschi V, Di Paolo M, Pomara C, Riezzo I, Turillazzi E, et al. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr Vasc Pharmacol. 2015;13(1):26–36.CrossRefPubMed
9.
Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713–35.CrossRefPubMed
10.
Wang X, Wang W, Li L, Perry G, H-g L, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2014;1842(8):1240–7.CrossRef
11.
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson’s disease. Front Neuroanat. 2015;9:91.PubMedPubMedCentral
12.
13.
Kaur H, Sarmah D, Saraf J, Vats K, Kalia K, Borah A, et al. Noncoding RNAs in ischemic stroke: time to translate. Ann N Y Acad Sci. 2018;1421:19–36.CrossRefPubMed
14.
Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2010;1802(1):80–91.CrossRef
15.
Sarmah D, Agrawal V, Rane P, Bhute S, Watanabe M, Kalia K, et al. Mesenchymal stem cell therapy in ischemic stroke: a meta-analysis of preclinical studies. Clin Pharmacol Ther. 2018;103(6):990–98.
16.
Sarmah D, Saraf J, Kaur H, Pravalika K, Tekade RK, Borah A, et al. Stroke management: an emerging role of nanotechnology. Micromachines. 2017;8(9):262.CrossRefPubMedCentral
17.
Bhattacharya P, Pandey AK, Paul S, Patnaik R, Yavagal DR. Aquaporin-4 inhibition mediates piroxicam-induced neuroprotection against focal cerebral ischemia/reperfusion injury in rodents. PLoS One. 2013;8(9):e73481.CrossRefPubMedPubMedCentral
18.
Sarmah D, Kaur H, Saraf J, Pravalika K, Goswami A, Kalia K, et al. Getting closer to an effective intervention of ischemic stroke: the big promise of stem cell. Transl Stroke Res. 2017:1–19.
19.
d'Adesky N, Bhattacharya P, Schatz M, Perez-Pinzon M, Bramlett H, Raval A. Nicotine alters estrogen receptor-Beta-regulated Inflammasome activity and exacerbates ischemic brain damage in female rats. Int J Mol Sci. 2018. https://​doi.​org/​10.​3390/​ijms19051330
20.
21.
Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke. Vasc Health Risk Manag. 2014;10:75.PubMedPubMedCentral
22.
Vu Q, Xie K, Eckert M, Zhao W, Cramer SC. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology. 2014;82(14):1277–86.CrossRefPubMedPubMedCentral
23.
Meurer WJ, Barth BE, Gaddis G, Vilke GM, Lam SH. Rapid systematic review: intra-arterial thrombectomy (“clot retrieval”) for selected patients with acute ischemic stroke. J Emerg Med. 2017;52(2):255–61.CrossRefPubMed
24.
Pravalika K, Sarmah D, Kaur H, Wanve M, Saraf J, Kalia K, et al. Myeloperoxidase and neurological disorder: a crosstalk. ACS Chem Neurosci. 2018;9(3):421–30.CrossRefPubMed
25.
Bhattacharya P, Pandey AK, Paul S, Patnaik R. Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia. Life Sci. 2014;100(2):97–109.CrossRefPubMed
26.
Bhattacharya P, Pandey AK, Paul S, Patnaik R. Neuroprotective potential of Piroxicam in cerebral ischemia: an in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a. Med Hypotheses. 2012;79(3):352–7.CrossRefPubMed
27.
Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis lecture. Stroke. 2003;34(1):214–23.CrossRefPubMed
28.
Paciaroni M, Caso V, Agnelli G. The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol. 2009;61(6):321–30.CrossRefPubMed
29.
Nour M, Scalzo F, Liebeskind DS. Ischemia-reperfusion injury in stroke. Interv Neurol. 2012;1(3–4):185–99.CrossRef
30.
31.
Pandey AK, Shukla SC, Bhattacharya P, Patnaik R. A possible therapeutic potential of quercetin through inhibition of μ-calpain in hypoxia induced neuronal injury: a molecular dynamics simulation study. Neural Regen Res. 2016;11(8):1247–53.CrossRefPubMedPubMedCentral
32.
33.
Atchaneeyasakul K, Guada L, Ramdas K, Watanabe M, Bhattacharya P, Raval AP, et al. Large animal canine endovascular ischemic stroke models: a review. Brain Res Bull. 2016;127:134–40.CrossRefPubMed
34.
Olmez I, Ozyurt H. Reactive oxygen species and ischemic cerebrovascular disease. Neurochem Int. 2012;60(2):208–12.CrossRefPubMed
35.
Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Hüttemann M. Molecular mechanisms of ischemia–reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol. 2013;47(1):9–23.CrossRefPubMed
36.
Gustafsson CM, Falkenberg M, Larsson N-G. Maintenance and expression of mammalian mitochondrial DNA. Annu Rev Biochem. 2016;85:133–60.CrossRefPubMed
37.
Kukat C, Davies KM, Wurm CA, Spåhr H, Bonekamp NA, Kühl I, et al. Cross-strand binding of TFAM to a single mtDNA molecule forms the mitochondrial nucleoid. Proc Natl Acad Sci. 2015;112(36):11288–93.CrossRefPubMedPubMedCentral
38.
Torralba D, Baixauli F, Sánchez-Madrid F. Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer. Front Cell Dev Biol. 2016;4(107):1–11.
39.
Ghezzi D, Zeviani M. Assembly factors of human mitochondrial respiratory chain complexes: physiology and pathophysiology. Adv Exp Med Biol. 2012;748:65–106.CrossRefPubMed
40.
Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. Free Radic Biol Med. 2000;29(3–4):285–94.CrossRefPubMed
41.
Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 2013;87(7):1157–80.CrossRefPubMed
42.
Selivanov VA, Votyakova TV, Pivtoraiko VN, Zeak J, Sukhomlin T, Trucco M, et al. Reactive oxygen species production by forward and reverse electron fluxes in the mitochondrial respiratory chain. PLoS Comput Biol. 2011;7(3):e1001115.CrossRefPubMedPubMedCentral
43.
Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair. 2006;5(2):145–52.CrossRefPubMed
44.
45.
Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:S210–S2.CrossRefPubMed
46.
Kussmaul L, Hirst J. The mechanism of superoxide production by NADH: ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci. 2006;103(20):7607–12.CrossRefPubMedPubMedCentral
47.
Lambert AJ, Brand MD. Inhibitors of the quinone-binding site allow rapid superoxide production from mitochondrial NADH: ubiquinone oxidoreductase (complex I). J Biol Chem. 2004;279(38):39414–20.CrossRefPubMed
48.
Dong L-F, Jameson VJ, Tilly D, Cerny J, Mahdavian E, Marín-Hernández A, et al. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem. 2011;286(5):3717–28.CrossRefPubMed
49.
50.
Niizuma K, Yoshioka H, Chen H, Kim GS, Jung JE, Katsu M, et al. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2010;1802(1):92–9.CrossRef
51.
Saito A, Hayashi T, Okuno S, Ferrand-Drake M, Chan PH. Interaction between XIAP and Smac/DIABLO in the mouse brain after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2003;23(9):1010–9.CrossRefPubMed
52.
Culmsee C, Zhu C, Landshamer S, Becattini B, Wagner E, Pellecchia M, et al. Apoptosis-inducing factor triggered by poly (ADP-ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci. 2005;25(44):10262–72.CrossRefPubMedPubMedCentral
53.
Zhou H, Wang J, Jiang J, Stavrovskaya IG, Li M, Li W, et al. N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J Neurosci. 2014;34(8):2967–78.CrossRefPubMedPubMedCentral
54.
Wang X, Figueroa BE, Stavrovskaya IG, Zhang Y, Sirianni AC, Zhu S, et al. Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke. 2009;40(5):1877–85.CrossRefPubMedPubMedCentral
55.
Martinvalet D, Zhu P, Lieberman J. Granzyme a induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity. 2005;22(3):355–70.CrossRefPubMed
56.
Philpott KL, McCarthy MJ, Klippel A, Rubin LL. Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons. J Cell Biol. 1997;139(3):809–15.CrossRefPubMedPubMedCentral
57.
Wang H-G, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284(5412):339–43.CrossRefPubMed
58.
59.
Mears JA, Lackner LL, Fang S, Ingerman E, Nunnari J, Hinshaw JE. Conformational changes in Dnm1 support a contractile mechanism for mitochondrial fission. Nat Struct Mol Biol. 2011;18(1):20–6.CrossRefPubMed
60.
Fannjiang Y, Cheng W-C, Lee SJ, Qi B, Pevsner J, McCaffery JM, et al. Mitochondrial fission proteins regulate programmed cell death in yeast. Genes Dev. 2004;18(22):2785–97.CrossRefPubMedPubMedCentral
61.
62.
Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature. 2005;434(7029):113–8.CrossRefPubMed
63.
Barja G. Endogenous oxidative stress: relationship to aging, longevity and caloric restriction. Ageing Res Rev. 2002;1(3):397–411.CrossRefPubMed
64.
Civitarese AE, Carling S, Heilbronn LK, Hulver MH, Ukropcova B, Deutsch WA, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4(3):e76.CrossRefPubMedPubMedCentral
65.
Zainal TA, Oberley TD, Allison DB, Szweda LI, Weindruch R. Caloric restriction of rhesus monkeys lowers oxidative damage in skeletal muscle. FASEB J. 2000;14(12):1825–36.CrossRefPubMed
66.
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71.CrossRefPubMed
67.
Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells antioxidant and antiapoptotic properties. J Biol Chem. 2001;276(7):4588–96.CrossRefPubMed
68.
James AM, Sharpley MS, Manas A-RB, Frerman FE, Hirst J, Smith RA, et al. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem. 2007;282(20):14708–18.CrossRefPubMed
69.
Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord. 2010;25(11):1670–4.CrossRefPubMed
70.
Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019–26.CrossRefPubMed
71.
Oyewole AO, Wilmot M-C, Fowler M, Birch-Machin MA. Comparing the effects of mitochondrial targeted and localized antioxidants with cellular antioxidants in human skin cells exposed to UVA and hydrogen peroxide. FASEB J. 2014;28(1):485–94.CrossRefPubMed
72.
Fang Y, Hu XH, Jia ZG, Xu MH, Guo ZY, Gao FH. Tiron protects against UVB-induced senescence-like characteristics in human dermal fibroblasts by the inhibition of superoxide anion production and glutathione depletion. Australas J Dermatol. 2012;53(3):172–80.CrossRefPubMed
73.
J Mailloux R. Application of mitochondria-targeted pharmaceuticals for the treatment of heart disease. Curr Pharm Des. 2016;22(31):4763–79.CrossRef
74.
Mao G, Kraus GA, Kim I, Spurlock ME, Bailey TB, Zhang Q, et al. A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice–3. J Nutr. 2010;140(8):1425–31.CrossRefPubMed
75.
Yin X, Manczak M, Reddy PH. Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease. Hum Mol Genet. 2016;25(9):1739–53.CrossRefPubMedPubMedCentral
76.
Powell RD, Swet JH, Kennedy KL, Huynh TT, Murphy MP, Mckillop IH, et al. MitoQ modulates oxidative stress and decreases inflammation following hemorrhage. J Trauma Acute Care Surg. 2015;78(3):573–9.CrossRefPubMed
77.
Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer’s disease neurons. J Alzheimers Dis. 2010;20(s2):S609–S31.CrossRefPubMedPubMedCentral
78.
Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2014;1842(8):1282–94.CrossRef
79.
Jauslin ML, Meier T, Smith RA, Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003;17(13):1972–4.CrossRefPubMed
80.
Diener H-C, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II trials. Stroke. 2008;39(6):1751–8.CrossRefPubMed
81.
Ley JJ, Vigdorchik A, Belayev L, Zhao W, Busto R, Khoutorova L, et al. Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics. J Pharmacol Exp Ther. 2005;313(3):1090–100.CrossRefPubMed
82.
Becker DA, Ley JJ, Echegoyen L, Alvarado R. Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J Am Chem Soc. 2002;124(17):4678–84.CrossRefPubMed
83.
Ley JJ, Belayev L, Saul I, Becker DA, Ginsberg MD. Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats: dose–response and therapeutic window. Brain Res. 2007;1180:101–10.CrossRefPubMedPubMedCentral
84.
Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectrums. 2009;14(S7):8–13.CrossRefPubMedPubMedCentral
85.
Kuzmicic J, del Campo A, López-Crisosto C, Morales PE, Pennanen C, Bravo-Sagua R, et al. Mitochondrial dynamics: a potential new therapeutic target for heart failure. Rev Esp Cardiol (English Edition). 2011;64(10):916–23.CrossRef
86.
Ou X, Lee MR, Huang X, Messina-Graham S, Broxmeyer HE. SIRT1 positively regulates autophagy and mitochondria function in embryonic stem cells under oxidative stress. Stem Cells. 2014;32(5):1183–94.CrossRefPubMedPubMedCentral
87.
Godoy J, Allard C, Arrázola M, Zolezzi J, Inestrosa N. SIRT1 protects dendrites, mitochondria and synapses from Aβ oligomers in hippocampal neurons. J Alzheimers Dis Park. 2013;3(4):1–9.
88.
Schenk S, McCurdy CE, Philp A, Chen MZ, Holliday MJ, Bandyopadhyay GK, et al. Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J Clin Invest. 2011;121(11):4281–8.CrossRefPubMedPubMedCentral
89.
Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006;444(7121):868–74.CrossRefPubMed
90.
91.
Albiero M, Avogaro A, Fadini GP. A perspective on sirtuins in the metabolic syndrome. Metab Syndr Relat Disord. 2015;13(4):161–4.CrossRefPubMed
92.
Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs. 2008;9(4):371–8.PubMed
93.
Khoury N, Koronowski KB, Young JI, Perez-Pinzon MA. The NAD+-dependent family of Sirtuins in cerebral ischemia and preconditioning. Antioxid Redox Signal. 2018;28(8):691–710.CrossRefPubMedPubMedCentral
94.
Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159(3):993–1002.CrossRefPubMed
95.
Reddy PH. Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. J Alzheimers Dis. 2014;40(2):245–56.CrossRefPubMedPubMedCentral
96.
Qi X, Qvit N, Su Y-C, Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013;126(3):789–802.CrossRefPubMedPubMedCentral
97.
Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008;14(2):193–204.CrossRefPubMedPubMedCentral
98.
Meuer K, Suppanz I, Lingor P, Planchamp V, Göricke B, Fichtner L, et al. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ. 2007;14(4):651–61.CrossRefPubMed
99.
Abbracchio MP, Burnstock G. Purinergic signalling: pathophysiological roles. Jpn J Pharmacol. 2001;78(2):113–45.CrossRef
100.
Fredholm BB. Purinoceptors in the nervous system. Basic & Clinical Pharmacology & Toxicology. 1995;76(4):228–39.CrossRef
101.
Watts LT, Lloyd R, Garling RJ, Duong T. Stroke neuroprotection: targeting mitochondria. Brain Sci. 2013;3(2):540–60.CrossRefPubMed
102.
Williams M, Burnstock G. Purinergic neurotransmission and neuromodulation: a historical perspective. In: Jacobson, KA and Jarvis, MF, editors. Purinergic approaches in experimental therapeutics. New York: Wiley-Liss; 1997. p. 3–26.
103.
104.
Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87(2):659–797.CrossRefPubMed
105.
Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y 1 receptor-null mice. J Clin Invest. 1999;104(12):1731–7.CrossRefPubMedPubMedCentral
106.
Fabre J-E, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y 1-deficient mice. Nat Med. 1999;5(10):1199–202.CrossRefPubMed
107.
108.
Zheng W, Watts LT, Holstein DM, Prajapati SI, Keller C, Grass EH, et al. Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria. PLoS One. 2010;5(12):e14401.CrossRefPubMedPubMedCentral
109.
Zheng W, Watts LT, Holstein DM, Wewer J, Lechleiter JD. P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. J Cereb Blood Flow Metab. 2013;33(4):600–11.CrossRefPubMedPubMedCentral
110.
Wu J, Holstein JD, Upadhyay G, Lin D-T, Conway S, Muller E, et al. Purinergic receptor-stimulated IP3-mediated Ca2+ release enhances neuroprotection by increasing astrocyte mitochondrial metabolism during aging. J Neurosci. 2007;27(24):6510–20.CrossRefPubMedPubMedCentral
111.
Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32–45.CrossRefPubMed
112.
Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan L-J, et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011;286(18):16504–15.CrossRefPubMedPubMedCentral
113.
Lin A-L, Poteet E, Du F, Gourav RC, Liu R, Wen Y, et al. Methylene blue as a cerebral metabolic and hemodynamic enhancer. PLoS One. 2012;7(10):e46585.CrossRefPubMedPubMedCentral
114.
Huang S, Du F, Shih Y-YI, Shen Q, Gonzalez-Lima F, Duong TQ. Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. NeuroImage. 2013;72:237–42.CrossRefPubMed
115.
Holley AK, Bakthavatchalu V, Velez-Roman JM, St Clair DK. Manganese superoxide dismutase: guardian of the powerhouse. Int J Mol Sci. 2011;12(10):7114–62.CrossRefPubMedPubMedCentral
116.
Holley AK, Dhar SK, Clair DKS. Manganese superoxide dismutase vs. p53: regulation of mitochondrial ROS. Mitochondrion. 2010;10(6):649–61.CrossRefPubMed
117.
Maier C, Hsieh L, Crandall T, Narasimhan P, Chan P. A new approach for the investigation of reperfusion-related brain injury. In: Portland press limited, vol. 34; 2006. p. 1366–9.
118.
Chan PH, Kawase M, Murakami K, Chen SF, Li Y, Calagui B, et al. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J Neurosci. 1998;18(20):8292–9.CrossRefPubMedPubMedCentral
119.
Ivanović-Burmazović I. Reactivity of manganese superoxide dismutase mimics toward superoxide and nitric oxide: Selectivity versus cross-reactivity. In: Advances in inorganic chemistry. New York: Elsevier; 2012. p. 53–95.
120.
Friedel FC, Lieb D, Ivanović-Burmazović I. Comparative studies on manganese-based SOD mimetics, including the phosphate effect, by using global spectral analysis. J Inorg Biochem. 2012;109:26–32.CrossRefPubMed
121.
Park W-C, Lim D-Y. Synthesis and SOD activity of manganese complexes of pentaaza macrocycles containing amino-and guanidino-auxiliary. Bull Kor Chem Soc. 2011;32(10):3787–9.CrossRef
122.
Shmonin A, Melnikova E, Galagudza M, Vlasov T. Characteristics of cerebral ischemia in major rat stroke models of middle cerebral artery ligation through craniectomy. Int J Stroke. 2014;9(6):793–801.CrossRefPubMed
123.
Huang HF, Guo F, Cao YZ, Shi W, Xia Q. Neuroprotection by manganese superoxide dismutase (MnSOD) mimics: antioxidant effect and oxidative stress regulation in acute experimental stroke. CNS Neurosci Ther. 2012;18(10):811–8.CrossRefPubMedPubMedCentral
124.
Kelso GF, Maroz A, Cochemé HM, Logan A, Prime TA, Peskin AV, et al. A mitochondria-targeted macrocyclic Mn (II) superoxide dismutase mimetic. Chem Biol. 2012;19(10):1237–46.CrossRefPubMed
125.
Kondo T, Reaume AG, Huang T-T, Carlson E, Murakami K, Chen SF, et al. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci. 1997;17(11):4180–9.CrossRefPubMedPubMedCentral
126.
Li M, Wang W, Mai H, Zhang X, Wang J, Gao Y, et al. Methazolamide improves neurological behavior by inhibition of neuron apoptosis in subarachnoid hemorrhage mice. Sci Rep. 2016;6:35055.CrossRefPubMedPubMedCentral
127.
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22.CrossRefPubMed
128.
Borlongan CV. Age of PISCES: stem-cell clinical trials in stroke. Lancet. 2016;388(10046):736–8.CrossRefPubMed
129.
Prasad K, Sharma A, Garg A, Mohanty S, Bhatnagar S, Johri S, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014;45(12):3618–24.CrossRefPubMed
130.
Hao L, Zou Z, Tian H, Zhang Y, Zhou H, Liu L. Stem cell-based therapies for ischemic stroke. Biomed Res Int. 2014;2014:1–17.
131.
Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535(7613):551–5.CrossRefPubMedPubMedCentral
132.
Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci. 2006;103(5):1283–8.CrossRefPubMedPubMedCentral
133.
Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759–65.CrossRefPubMedPubMedCentral
134.
Ahmad T, Mukherjee S, Pattnaik B, Kumar M, Singh S, Rehman R et al. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J. 2014;33(9):994–1010.
135.
Cho YM, Kim JH, Kim M, Park SJ, Koh SH, Ahn HS, et al. Mesenchymal stem cells transfer mitochondria to the cells with virtually no mitochondrial function but not with pathogenic mtDNA mutations. PLoS One. 2012;7(3):e32778.CrossRefPubMedPubMedCentral
136.
Lin H-Y, Liou C-W, Chen S-D, Hsu T-Y, Chuang J-H, Wang P-W, et al. Mitochondrial transfer from Wharton's jelly-derived mesenchymal stem cells to mitochondria-defective cells recaptures impaired mitochondrial function. Mitochondrion. 2015;22:31–44.CrossRefPubMed
137.
Acquistapace A, Bru T, Lesault PF, Figeac F, Coudert AE, Le Coz O, et al. Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells. 2011;29(5):812–24.CrossRefPubMedPubMedCentral
138.
Li X, Zhang Y, Yeung SC, Liang Y, Liang X, Ding Y, et al. Mitochondrial transfer of induced pluripotent stem cell-derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke-induced damage. Am J Respir Cell Mol Biol. 2014;51(3):455–65.CrossRefPubMed
139.
Rogers RS, Bhattacharya J. When cells become organelle donors. Physiology. 2013;28(6):414–22.CrossRefPubMed
140.
Berridge MV, McConnell MJ, Grasso C, Bajzikova M, Kovarova J, Neuzil J. Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches. Curr Opin Genet Dev. 2016;38:75–82.CrossRefPubMed
141.
Liu K, Ji K, Guo L, Wu W, Lu H, Shan P, et al. Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia–reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer. Microvasc Res. 2014;92:10–8.CrossRefPubMed
142.
Han H, Hu J, Yan Q, Zhu J, Zhu Z, Chen Y, et al. Bone marrow-derived mesenchymal stem cells rescue injured H9c2 cells via transferring intact mitochondria through tunneling nanotubes in an in vitro simulated ischemia/reperfusion model. Mol Med Rep. 2016;13(2):1517–24.CrossRefPubMed
143.
Plotnikov E, Khryapenkova T, Vasileva A, Marey M, Galkina S, Isaev N, et al. Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. J Cell Mol Med. 2008;12(5a):1622–31.CrossRefPubMed
144.
Mahrouf-Yorgov M, Augeul L, Da Silva CC, Jourdan M, Rigolet M, Manin S, et al. Mesenchymal stem cells sense mitochondria released from damaged cells as danger signals to activate their rescue properties. Cell Death Differ. 2017;24:1224–38.CrossRefPubMedPubMedCentral
145.
Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood. 2016;128(2):253–64.CrossRefPubMed
146.
Bukoreshtliev NV, Wang X, Hodneland E, Gurke S, Barroso JF, Gerdes H-H. Selective block of tunneling nanotube (TNT) formation inhibits intercellular organelle transfer between PC12 cells. FEBS Lett. 2009;583(9):1481–8.CrossRefPubMed
147.
Rustom A, Saffrich R, Markovic I, Walther P, Gerdes H-H. Nanotubular highways for intercellular organelle transport. Science. 2004;303(5660):1007–10.CrossRefPubMed
148.
He K, Shi X, Zhang X, Dang S, Ma X, Liu F, et al. Long-distance intercellular connectivity between cardiomyocytes and cardiofibroblasts mediated by membrane nanotubes. Cardiovasc Res. 2011;92(1):39–47.CrossRefPubMed
149.
Sun X, Wang Y, Zhang J, Tu J, Wang X, Su X, et al. Tunneling-nanotube direction determination in neurons and astrocytes. Cell Death Dis. 2012;3(12):e438.CrossRefPubMedPubMedCentral
150.
Lou E, Fujisawa S, Morozov A, Barlas A, Romin Y, Dogan Y, et al. Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS One. 2012;7(3):e33093.CrossRefPubMedPubMedCentral
151.
Mittelbrunn M, Sánchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol. 2012;13(5):328–35.CrossRefPubMedPubMedCentral
152.
Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J Clin Invest. 2016;126(4):1139–43.CrossRefPubMedPubMedCentral
153.
Jayaprakash AD, Benson EK, Gone S, Liang R, Shim J, Lambertini L, et al. Stable heteroplasmy at the single-cell level is facilitated by intercellular exchange of mtDNA. Nucleic Acids Res. 2015;43(4):2177–87.CrossRefPubMedPubMedCentral
154.
Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, Perry A, et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci. 2003;100(5):2397–402.CrossRefPubMedPubMedCentral
155.
Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003;425(6961):968–73.CrossRefPubMed
156.
Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci. 2003;100(21):12313–8.CrossRefPubMedPubMedCentral
157.
Vassilopoulos G, Wang P-R, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422(6934):901–4.CrossRefPubMed
158.
Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 2003;422(6934):897–901.CrossRefPubMed
159.
Nakajima A, Kurihara H, Yagita H, Okumura K, Nakano H. Mitochondrial extrusion through the cytoplasmic vacuoles during cell death. J Biol Chem. 2008;283(35):24128–35.CrossRefPubMedPubMedCentral
160.
Lyamzaev KG, Nepryakhina OK, Saprunova VB, Bakeeva LE, Pletjushkina OY, Chernyak BV, et al. Novel mechanism of elimination of malfunctioning mitochondria (mitoptosis): formation of mitoptotic bodies and extrusion of mitochondrial material from the cell. Biochim Biophys Acta (BBA)-Bioenergetics. 2008;1777(7):817–25.CrossRef
161.
Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med. 2008;14(9):949–53.CrossRefPubMed
162.
Boudreau LH, Duchez A-C, Cloutier N, Soulet D, Martin N, Bollinger J, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase a 2 to promote inflammation. Blood. 2014;124(14):2173–83.CrossRefPubMedPubMedCentral
163.
164.
Babenko VA, Silachev DN, Popkov VA, Zorova LD, Pevzner IB, Plotnikov EY, et al. Miro1 enhances mitochondria transfer from multipotent mesenchymal stem cells (MMSC) to neural cells and improves the efficacy of cell recovery. Molecules. 2018;23(3):687.CrossRefPubMedCentral
Metadaten
Titel
Mitochondrial Dysfunction in Stroke: Implications of Stem Cell Therapy
verfasst von
Deepaneeta Sarmah
Harpreet Kaur
Jackson Saraf
Kanchan Vats
Kanta Pravalika
Madhuri Wanve
Kiran Kalia
Anupom Borah
Akhilesh Kumar
Xin Wang
Dileep R. Yavagal
Kunjan R. Dave
Pallab Bhattacharya
Publikationsdatum
20.06.2018
Verlag
Springer US
Erschienen in
Translational Stroke Research / Ausgabe 2/2019
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-018-0642-y

Weitere Artikel der Ausgabe 2/2019

Translational Stroke Research 2/2019 Zur Ausgabe

Short Communication

Post-stroke Recrudescence from Infection: an Immunologic Mechanism?

Original Article

Radiologic Cerebral Reperfusion at 24 h Predicts Good Clinical Outcome

Original Article

Enriched Environment Elicits Proangiogenic Mechanisms After Focal Cerebral Ischemia

Original Article

Redistribution of Mature Smooth Muscle Markers in Brain Arteries in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy

Original Article

Genetic and Environmental Contributions to Variation in the Posterior Communicating Collaterals of the Circle of Willis

Methods Paper

Intrathecal Injection of Allogenic Bone Marrow-Derived Mesenchymal Stromal Cells in Treatment of Patients with Severe Ischemic Stroke: Study Protocol for a Randomized Controlled Observer-Blinded Trial

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise